ALNYLAM PHARMACEUTICALS, INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $95.67 million as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-12
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $95.67M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $113.06M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $133.43M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $156.83M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $95.67M 10-K · filed 2026-02-12 |
| 2024-12-31 | $113.06M 10-K · filed 2025-02-13 |
| 2023-12-31 | $133.43M 10-K · filed 2024-02-15 |
| 2022-12-31 | $156.83M 10-K · filed 2023-02-23 |
| 2021-12-31 | $181.69M 10-K · filed 2022-02-10 |
| 2020-12-31 | $206.42M 10-K · filed 2021-02-11 |
| 2019-12-31 | $225.87M 10-K · filed 2020-02-13 |
| 2019-09-30 | $231.65M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $237.90M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $244.49M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |